The Technical Analyst
Hancock Jaffe [HJLI]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Hancock Jaffe Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.98% $10.38
America/New_York / 1 okt 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 98.32 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Aug 11, 2021 |
| SharesOutstanding: | 9.47 mill |
| Avg Daily Volume: | 0.777 mill |
| RATING 2022-02-09 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.89 - 10.87 ( +/- 4.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-05-18 | Berman Robert Andrew | Buy | 3 000 | Common Stock, $0.00001 par value |
| 2020-07-18 | Duhay Francis | Buy | 62 500 | Common Stock |
| 2020-07-18 | Duhay Francis | Buy | 100 000 | Stock Option |
| 2019-06-07 | Biodyne Holding, S.a. | Sell | 684 813 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 4 transactions |
| Buy: 165 500 | Sell: 684 813 |
Forecast:
01:40 - $8.83
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.38 (-1.98% ) |
| Volume | 0.222 mill |
| Avg. Vol. | 0.777 mill |
| % of Avg. Vol | 28.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HJLI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HJLI
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.
Latest Press Releases
2021-09-24 09:00:00 - Press Release
Hancock Jaffe To Participate In The Duologue Series Virtual Webinar Hosted By Ladenburg Thalmann
Live webinar followed by q&a on monday, september 27th at 1:00 pm et with robert berman chief executive officer of hancock jaffe laboratories irvine, ca / accesswire / september 24, 2021 / hancock jaffe laboratories, inc. (nasdaq:hjli) ("hancock jaffe" or the "company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that robert berman, ceo of hancock jaffe will participate in the duologue series hosted by ladenburg thalmann on monday, september 27, 2021 at 1:00 pm et. the webinar will be moderated by jeffrey s.
2021-09-15 08:05:00 - Press Release
Hancock Jaffe To Host Corporate Update Conference Call And Webcast On September 21, 2021
Conference call with live video webcast to be held on tuesday, september 21st at 4:30 p.m. et irvine, ca / accesswire / september 15, 2021 / hancock jaffe laboratories, inc. (nasdaq:hjli) ("hancock jaffe" or the "company"), a developer of medical devices that restore cardiac and vascular health, today announced that hancock jaffe management will host a corporate update conference call with a live video webcast on tuesday, september 21, 2021 at 4:30 p.m.
2021-09-07 08:05:00 - Press Release
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Irvine, ca / accesswire / september 7, 2021 / hancock jaffe laboratories, inc. (nasdaq:hjli), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by perceptive advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under nasdaq rules. the offering consists of 2,540,650 shares of common stock and pre-funded warrants at a purchase price of $7.8720 per share.
2021-08-19 08:00:00 - Press Release
Hancock Jaffe Presents New Positive Two-year Venovalve Data At The Society For Vascular Surgery Annual Meeting
Two-year venovalve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences no safety issues occurred during the one-year reporting period following the study completion irvine, ca / accesswire / august 19, 2021 / hancock jaffe laboratories, inc. (nasdaq:hjli) ("hancock jaffe" or the "company"), a developer of medical devices that restore cardiac and vascular health, announced that promising two-year post-venovalve® implantation data is being presented today at the society for vascular surgery® (svs) annual meeting in san diego, ca by dr...
2021-08-03 08:05:00 - Press Release
Fda Grants Breakthrough Device Designation Status For Hancock Jaffe's Venovalve
- goal of fda breakthrough device program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - company preparing to begin savve u.s. pivotal trial for venovalve - venovalve is a potential treatment for approximately 2.4 million u.s. patients that suffer from severe chronic venous insufficiency in the deep veins of their legs irvine, ca / accesswire / august 3, 2021 / hancock jaffe laboratories, inc. (nasdaq:hjli) ("hancock jaffe" or the "company"), a developer of medical devices that restore cardiac and vascular health, today announced that the u.s. food and drug administration (fda) has granted breakthrough device designation status to the venovalve®, the company's lead product, which is currently set to begin its u...
Latest News
2021-09-24 09:00:00 - Accesswire
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate in The Duologue Series hosted by Ladenburg Thalmann on Monday, September 27, 2021 at 1:00 PM ET. The webinar will be moderated by Jeffrey S.
2021-09-22 07:09:30 - Benzinga
Hancock Jaffe To Rebrand As enVVeno Medical
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will change its name to enVVeno Medical Corporation and start under a new ticker, "NVNO," from October 1. The Company will also narrow its strategic focus to reflect its decision to go all-in on the VenoValve and treat venous disease.
2021-09-15 08:05:00 - Accesswire
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at 4:30 p.m.
2021-09-08 19:43:33 - Seeking Alpha
Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
Hancock Jaffe Laboratories develops nature-mimetic bioprosthetics for patients with debilitating cardiovascular diseases. The Company got IDE approval in April 2021 to begin a pivotal trial of VenoValve in the U.S.
2021-09-07 08:05:00 - Accesswire
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules. The offering consists of 2,540,650 shares of common stock and pre-funded warrants at a purchase price of $7.8720 per share.
2021-08-19 11:49:55 - Benzinga
Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.
2021-08-19 08:00:00 - Accesswire
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting
Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences No safety issues occurred during the one-year reporting period following the study completion IRVINE, CA / ACCESSWIRE / August 19, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, announced that promising two-year post-VenoValve® implantation data is being presented today at the Society for Vascular Surgery® (SVS) Annual Meeting in San Diego, CA by Dr...
2021-08-03 08:35:43 - Pulse2
HJLI Stock Price Increases Over 35% Pre-Market: Why It Happened
The stock price of Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) increased by over 35% pre-market. This is why it happened.
2021-08-03 08:05:00 - Accesswire
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve
- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE U.S. pivotal trial for VenoValve - VenoValve is a potential treatment for approximately 2.4 million U.S. patients that suffer from severe Chronic Venous Insufficiency in the deep veins of their legs IRVINE, CA / ACCESSWIRE / August 3, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the VenoValve®, the Company's lead product, which is currently set to begin its U...
2021-07-08 09:05:00 - Accesswire
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Live webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Robert Berman, CEO of Hancock Jaffe will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021 at 1:00 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.